GPCR
NASDAQStructure Therapeutics Inc.
$45.51-1.52 (-3.23%)
News25/Ratings12
Price$45.51-1.27 (-2.71%)
01:30 PM07:45 PM
News · 26 weeks50-60%
2025-10-262026-04-19
Mix2990d
- Insider15(52%)
- SEC Filings6(21%)
- Other5(17%)
- Earnings1(3%)
- Analyst1(3%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form DEF 14A filed by Structure Therapeutics Inc.DEF 14A - Structure Therapeutics Inc. (0001888886) (Filer)
- INSIDERCOO & GC Lang Matthew was granted 184,614 units of Ordinary Shares (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lang Matthew3 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Fmr Llc4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- SECStructure Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Structure Therapeutics Inc. (0001888886) (Filer)
- PRStructure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General CounselSAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel. Mr. Lang joins Structure Therapeutics with more than fifteen years of executive leadership experience across global biopharmaceutical organizations, with deep expertise spanning legal, corporate strategy, compliance, risk management, and business development. "Matt is a proven leader with a strong track record of guiding organizations through growth a
- ANALYSTWolfe Research initiated coverage on Structure TherapeuticsWolfe Research initiated coverage of Structure Therapeutics with a rating of Peer Perform
- INSIDERSEC Form 4 filed by Hall Ashley4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Lin Xichen4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Ma Yingli4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Coll Crespo Blas4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Yoon Jun4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERSEC Form 4 filed by Stevens Raymond C4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- SECStructure Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Structure Therapeutics Inc. (0001888886) (Filer)
- PRStructure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, AleniglipronPlacebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral GLP-1RAs and comparable efficacy to injectable GLP1-RAs Continued weight loss up to 16.2% (40.5 lbs) observed with 120 mg dose in the ACCESS Open Label Extension (OLE) study at 56 weeks, with no evidence of weight loss plateau Updated interim data from ACCESS OLE and Body Composition studies continue to support improved tolerability and low (2.0 – 3.4%) study drug discontinuations due to adverse events with the lower 2.5 mg starting dose End-of-Phase 2 meeting with FDA scheduled in the second
- INSIDERCHIEF TECHNOLOGY OFFICER Ma Yingli covered exercise/tax liability with 11,313 units of Ordinary Shares, decreasing direct ownership by 10% to 107,391 units (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Coll Crespo Blas covered exercise/tax liability with 11,826 units of Ordinary Shares, decreasing direct ownership by 5% to 204,981 units (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Stevens Raymond C covered exercise/tax liability with 53,454 units of Ordinary Shares, decreasing direct ownership by 4% to 1,141,376 units (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Lin Xichen covered exercise/tax liability with 18,735 units of Ordinary Shares, decreasing direct ownership by 9% to 185,592 units (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERChief Development Officer Hall Ashley covered exercise/tax liability with 4,836 units of Ordinary Shares, decreasing direct ownership by 4% to 107,481 units (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Yoon Jun covered exercise/tax liability with 22,305 units of Ordinary Shares, decreasing direct ownership by 2% to 1,297,571 units (SEC Form 4)4 - Structure Therapeutics Inc. (0001888886) (Issuer)
- SECSEC Form S-8 filed by Structure Therapeutics Inc.S-8 - Structure Therapeutics Inc. (0001888886) (Filer)
- SECSEC Form 10-K filed by Structure Therapeutics Inc.10-K - Structure Therapeutics Inc. (0001888886) (Filer)
- SECStructure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Structure Therapeutics Inc. (0001888886) (Filer)
- PRStructure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent HighlightsPositive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS II study with higher doses expected in Q1 2026 Aleniglipron Phase 3 initiation expected in 2H 2026 Initial data from the ongoing Phase 1 study of oral small molecule amylin receptor agonist ACCG-2671 and Phase 1 initiation of second oral amylin compound ACCG-3535 expected in 2H 2026 Cash, cash equivalents and short-term investments of $1.4 billion as of December 31, 2025, expected to provide cash runway through the end of 2028 SAN FRANCISCO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Structure Th